Literature DB >> 22390879

Phencyclidine/schizophrenia: one view toward the past, the other to the future.

Edward F Domino1, Elliot D Luby.   

Abstract

The history of the chemical synthesis and animal/human pharmacology of phencyclidine is documented. From its early use as a general anesthetic, chemical model of schizophrenia, and drug of abuse, phencyclidine has had a checkered history. Research with this agent and its chemical derivatives like ketamine have provided a solid foundation for just a beginning to understanding the neuropathology of schizophrenia.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22390879      PMCID： PMC3446224          DOI： 10.1093/schbul/sbs011

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN： 0586-7614            Impact factor:   9.306


  40 in total

Review 1.  Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?

Authors:  F R Sharp; M Tomitaka; M Bernaudin; S Tomitaka
Journal:  Trends Neurosci       Date:  2001-06       Impact factor: 13.837

2.  THE SYNTHESIS OF PHENCYCLIDINE AND OTHER 1-ARYLCYCLOHEXYLAMINES.

Authors:  V H MADDOX; E F GODEFROI; R F PARCELL
Journal:  J Med Chem       Date:  1965-03       Impact factor: 7.446

3.  The pharmacology of 1-(1-phenylcyclohexyl) piperidine-HCl.

Authors:  G CHEN; C R ENSOR; D RUSSELL; B BOHNER
Journal:  J Pharmacol Exp Ther       Date:  1959-11       Impact factor: 4.030

4.  Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception.

Authors:  G ROSENBAUM; B D COHEN; E D LUBY; J S GOTTLIEB; D YELEN
Journal:  AMA Arch Gen Psychiatry       Date:  1959-12

5.  Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects.

Authors:  F M Benes; S L Vincent; A Marie; Y Khan
Journal:  Neuroscience       Date:  1996-12       Impact factor: 3.590

6.  Schizophrenia genes - famine to feast.

Authors:  Richard E Straub; Daniel R Weinberger
Journal:  Biol Psychiatry       Date:  2006-07-15       Impact factor: 13.382

7.  The effects of drugs on objective measures of thought disorder in schizophrenic patients.

Authors:  R W Payne
Journal:  Psychopharmacologia       Date:  1972

8.  Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: a 123I-iomazenil SPET study.

Authors:  S Ball; G F Busatto; A S David; S H Jones; D R Hemsley; L S Pilowsky; D C Costa; P J Ell; R W Kerwin
Journal:  Biol Psychiatry       Date:  1998-01-15       Impact factor: 13.382

9.  GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression.

Authors:  Jong H Yoon; Richard J Maddock; Ariel Rokem; Michael A Silver; Michael J Minzenberg; J Daniel Ragland; Cameron S Carter
Journal:  J Neurosci       Date:  2010-03-10       Impact factor: 6.167

Review 10.  The NMDA antagonist model for schizophrenia: promise and pitfalls.

Authors:  W M Abi-Saab; D C D'Souza; B Moghaddam; J H Krystal
Journal:  Pharmacopsychiatry       Date:  1998-07       Impact factor: 5.788
View more
  23 in total

Review 1.  Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits.

Authors:  Bernat Kocsis; Ritchie E Brown; Robert W McCarley; Mihaly Hajos
Journal:  CNS Neurosci Ther       Date:  2013-04-24       Impact factor: 5.243

2.  Effects of ketamine on EEG in baboons with genetic generalized epilepsy.

Authors:  Shaila Gowda; C Ákos Szabó
Journal:  Epilepsy Res       Date:  2019-04-18       Impact factor: 3.045

Review 3.  Could Dietary Glutamate Play a Role in Psychiatric Distress?

Authors:  A Zarina Kraal; Nicole R Arvanitis; Andrew P Jaeger; Vicki L Ellingrod
Journal:  Neuropsychobiology       Date:  2019-01-30       Impact factor: 2.328

Review 4.  Ketamine and phencyclidine: the good, the bad and the unexpected.

Authors:  D Lodge; M S Mercier
Journal:  Br J Pharmacol       Date:  2015-07-28       Impact factor: 8.739

5.  Ketamine induced converged synchronous gamma oscillations in the cortico-basal ganglia network of nonhuman primates.

Authors:  Maya Slovik; Boris Rosin; Shay Moshel; Rea Mitelman; Eitan Schechtman; Renana Eitan; Aeyal Raz; Hagai Bergman
Journal:  J Neurophysiol       Date:  2017-05-03       Impact factor: 2.714

6.  Afferent drive of medial prefrontal cortex by hippocampus and amygdala is altered in MAM-treated rats: evidence for interneuron dysfunction.

Authors:  Behnaz Esmaeili; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2013-03-07       Impact factor: 7.853

7.  Twenty-five years of glutamate in schizophrenia: are we there yet?

Authors:  Daniel C Javitt
Journal:  Schizophr Bull       Date:  2012-09       Impact factor: 9.306

Review 8.  Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

Authors:  Frank S Menniti; Craig W Lindsley; P Jeffrey Conn; Jayvardhan Pandit; Panayiotis Zagouras; Robert A Volkmann
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

9.  NMDA Receptors in the Central Nervous System.

Authors:  Kasper B Hansen; Feng Yi; Riley E Perszyk; Frank S Menniti; Stephen F Traynelis
Journal:  Methods Mol Biol       Date:  2017

10.  VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy.

Authors:  Hilary Highfield Nickols; Joannes P Yuh; Karen J Gregory; Ryan D Morrison; Brittney S Bates; Shaun R Stauffer; Kyle A Emmitte; Michael Bubser; Weimin Peng; Michael T Nedelcovych; Analisa Thompson; Xiaohui Lv; Zixiu Xiang; J Scott Daniels; Colleen M Niswender; Craig W Lindsley; Carrie K Jones; P Jeffrey Conn
Journal:  J Pharmacol Exp Ther       Date:  2015-10-26       Impact factor: 4.030
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.